Compare AT&T Inc. (T) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance

AT&T (T) trades at $23.08, up 2.62% today, with strong fundamentals including a P/E of 7.54 and net income margin of 16.94%. Recent earnings beat expectations, with Q2 2026 EPS of $0.65 versus $0.59 expected. Technical indicators show a bearish overall signal despite bullish oscillators. The company maintains robust cash flow with $15.12B net cash flow in 2025 and recently announced a $3B fiber deal with Corning to support AI infrastructure growth.

Outlook remains mixed with analyst consensus price target of $27.39 offering 19% upside potential, though technical weakness and competitive pressures pose risks. The stock's 4% dividend yield provides income support, but debt levels and legacy revenue declines require monitoring. Fiber expansion and wireless growth present opportunities amid challenging market conditions.

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.